Literature DB >> 28286270

USP39, a direct target of microRNA-133a, promotes progression of pancreatic cancer via the AKT pathway.

Jing Cai1, Tiande Liu2, Peng Huang3, Wei Yan4, Changkuo Guo1, Le Xiong1, Anwen Liu5.   

Abstract

Ubiquitin specific protease 39 (USP39) is one of the deubiquitinating enzymes without ubiquitin protease activity, which has been implicated in the progression of several cancers. However, the role of USP39 in pancreatic cancer (PC) is largely unknown. In present study, we found that USP39 expression was elevated in PC tissues than adjacent non-tumor tissues. Importantly, we demonstrated that overexpression of USP39 is closely correlated with tumor progression and poor survival in PC patients. Furthermore, high USP39 expression was observed in PC cell lines and ectopic expression of USP39 significantly enhanced in vitro cell proliferation and promoted in vivo tumor growth, whereas silencing USP39 suppressed growth of PC cells. Besides, our experimental data revealed that knockdown of USP39 induced cell apoptosis through inhibition of AKT signaling pathway in PC cells. Moreover, USP39 was a direct target of miR-133a, a microRNA that has been reported to be involved in progression of PC. Taken together, our data provide a novel PC regulatory axis that is miR-133a/USP39, the dysfunction of which drives diverse aspects of the progression of PC.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  AKT pathway; Apoptosis; Pancreatic cancer; USP39; miR-133a

Mesh:

Substances:

Year:  2017        PMID: 28286270     DOI: 10.1016/j.bbrc.2017.03.025

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  11 in total

1.  USP39 facilitates breast cancer cell proliferation through stabilization of FOXM1.

Authors:  Zhenwang Zhang; Wu Liu; Xiajun Bao; Tian Sun; Jiawei Wang; Mengxi Li; Chao Liu
Journal:  Am J Cancer Res       Date:  2022-08-15       Impact factor: 5.942

Review 2.  The role of deubiquitinating enzymes in cancer drug resistance.

Authors:  Parthasaradhireddy Tanguturi; Kye-Seong Kim; Suresh Ramakrishna
Journal:  Cancer Chemother Pharmacol       Date:  2020-03-07       Impact factor: 3.333

3.  The long coding RNA AFAP1-AS1 promotes tumor cell growth and invasion in pancreatic cancer through upregulating the IGF1R oncogene via sequestration of miR-133a.

Authors:  Bo Chen; Qinhua Li; Yongping Zhou; Xujing Wang; Qiqi Zhang; Yongkun Wang; Huiren Zhuang; Xiaohua Jiang; Wujun Xiong
Journal:  Cell Cycle       Date:  2018       Impact factor: 4.534

4.  miR-133a, directly targeted USP39, suppresses cell proliferation and predicts prognosis of gastric cancer.

Authors:  Xiang Dong; Hailong Su; Feng Jiang; Haiyan Li; Guangwen Shi; Lijuan Fan
Journal:  Oncol Lett       Date:  2018-04-04       Impact factor: 2.967

5.  USP39 regulates the cell cycle, survival, and growth of human leukemia cells.

Authors:  Chunxia Liu; Xiaojian Yao; Ming Li; Yaming Xi; Li Zhao
Journal:  Biosci Rep       Date:  2019-04-05       Impact factor: 3.840

6.  RNA splicing factor USP39 promotes glioma progression by inducing TAZ mRNA maturation.

Authors:  Kaikai Ding; Jianxiong Ji; Xin Zhang; Bin Huang; Anjing Chen; Di Zhang; Xingang Li; Xinyu Wang; Jian Wang
Journal:  Oncogene       Date:  2019-07-22       Impact factor: 9.867

7.  MicroRNA-133a inhibits the proliferation of non-small cell lung cancer by targeting YES1.

Authors:  Yuyao Shen; Fangwei Chen; Yanchao Liang
Journal:  Oncol Lett       Date:  2019-11-01       Impact factor: 2.967

8.  Knocking down USP39 Inhibits the Growth and Metastasis of Non-Small-Cell Lung Cancer Cells through Activating the p53 Pathway.

Authors:  Jiahui Yuan; Gongye Zhang; Xiaomei Li; Qiujuan Ma; Weipeng Cheng; Weiwei Wang; Bing Zhang; Tianhui Hu; Gang Song
Journal:  Int J Mol Sci       Date:  2020-11-25       Impact factor: 5.923

9.  High Expression of Ubiquitin-Specific Protease 39 and Its Roles in Prognosis in Patients with Hepatocellular Carcinoma.

Authors:  Yu Liao; Lin Li; Huabao Liu; Yi Song
Journal:  Evid Based Complement Alternat Med       Date:  2021-12-27       Impact factor: 2.629

Review 10.  Identifying Novel Actionable Targets in Colon Cancer.

Authors:  Maria Grazia Cerrito; Emanuela Grassilli
Journal:  Biomedicines       Date:  2021-05-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.